|Bid||25.85 x 2200|
|Ask||28.72 x 800|
|Day's Range||28.27 - 28.62|
|52 Week Range||22.70 - 29.26|
|Beta (3Y Monthly)||0.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.00|
After several tireless days we have finished crunching the numbers from the more than 700 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of September 30. The results of that effort will be put on display in this […]
NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NxStage (NXTM) delivered earnings and revenue surprises of 150.00% and 0.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
NxStage (NXTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
"We are really beginning to see a shift toward using innovative telehealth solutions to help improve patient outcomes with home dialysis," said Dr. Michael Kraus, Associate Chief Medical Officer for NxStage. "Nx2me is an intuitive tool to support and proactively engage with home hemodialysis patients. A key component of the Nx2me platform is the Nx2me iPad® app, which is designed to increase patients' ease of use of home therapy by capturing treatment data and wirelessly sending it to their center after each treatment, thereby reducing the need for paper flow sheets.
Patients 20-44 years of age experienced 44% lower risk of death LAWRENCE, Mass. , Oct. 23, 2018 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing ...
LAWRENCE, Mass., Oct. 18, 2018 /PRNewswire/ -- NxStage Medical, Inc. (NXTM), a leading medical technology company focused on advancing renal care, announced new findings demonstrating significant survival benefit and lower cardiovascular hospitalization with more frequent home hemodialysis using the NxStage® System One™ within the skilled nursing facility setting. The data, developed in collaboration with Affiliated Dialysis Centers, LLC, will be presented by NxStage at the American Society of Nephrology (ASN) Kidney Week 2018 Annual Meeting on October 26th. Conference attendees can meet with NxStage representatives at booth 1841 to discuss the recent findings.
NxStage (NXTM) delivered earnings and revenue surprises of 20.00% and 1.54%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
WallStEquities.com scans Illumina Inc. (NASDAQ: ILMN), Intuitive Surgical Inc. (NASDAQ: ISRG), Merit Medical Systems Inc. (NASDAQ: MMSI), and Nxstage Medical Inc. (NASDAQ: NXTM). Companies in the Medical Instruments and Supplies manufacturing industry primarily research, develop, and produce nonelectronic medical, surgical, dental and veterinary instruments and apparatus, such as syringes, anesthesia apparatus, blood transfusion equipment, catheters, surgical clamps, and medical thermometers.All you have to do is sign up today for this free limited time offer by clicking the link below.